ATE530670T1 - Verfahren zur vorhersage der ansprechempfindlichkeit auf tnf-blocker - Google Patents

Verfahren zur vorhersage der ansprechempfindlichkeit auf tnf-blocker

Info

Publication number
ATE530670T1
ATE530670T1 AT07789647T AT07789647T ATE530670T1 AT E530670 T1 ATE530670 T1 AT E530670T1 AT 07789647 T AT07789647 T AT 07789647T AT 07789647 T AT07789647 T AT 07789647T AT E530670 T1 ATE530670 T1 AT E530670T1
Authority
AT
Austria
Prior art keywords
predicting
responsibility
tnf blockers
genes
patient
Prior art date
Application number
AT07789647T
Other languages
English (en)
Inventor
Jean-Philippe Salier
Maryvonne Daveau
Anne-Christine Gauthier-Jauneau
Olivier Vittecoq
Loot Xavier Le
Alain Daragon
Othmane Mejjad
Thierry Lequerre
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE530670T1 publication Critical patent/ATE530670T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analyzing Materials Using Thermal Means (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT07789647T 2006-05-16 2007-05-15 Verfahren zur vorhersage der ansprechempfindlichkeit auf tnf-blocker ATE530670T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06290789A EP1857559A1 (de) 2006-05-16 2006-05-16 Verfahren zur Vorhersage der Sensivität gegenüber TNF-alpha-Blockern
PCT/IB2007/002373 WO2007135568A2 (en) 2006-05-16 2007-05-15 A METHOD FOR PREDICTING RESPONSIVENESS TO TNFα BLOCKING AGENTS

Publications (1)

Publication Number Publication Date
ATE530670T1 true ATE530670T1 (de) 2011-11-15

Family

ID=36764554

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07789647T ATE530670T1 (de) 2006-05-16 2007-05-15 Verfahren zur vorhersage der ansprechempfindlichkeit auf tnf-blocker

Country Status (7)

Country Link
US (1) US7985549B2 (de)
EP (2) EP1857559A1 (de)
AT (1) ATE530670T1 (de)
CA (1) CA2652087A1 (de)
DK (1) DK2019872T3 (de)
ES (1) ES2375865T3 (de)
WO (1) WO2007135568A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009013410A (es) * 2007-06-08 2010-03-22 Biogen Idec Inc Biomarcadores para predecir capacidad de respuesta anti-tnf o sin capacidad de respuesta.
WO2009117791A2 (en) * 2008-03-28 2009-10-01 Katholieke Universiteit Leuven Mucosal gene signatures
US20110177966A1 (en) * 2008-06-12 2011-07-21 Xavier Le Loet method for predicting the response to a treatment with anakinra
ES2335381B1 (es) * 2008-09-24 2011-02-28 Fundacio Institut De Recerca De L'hospital Universitari Vall D'hebron Metodo in vitro y kit para el pronostico o prediccion de la respuestapor parte de pacientes con artritis reumatoide al tratamiento con agentes bloqueantes del factor tnfalfa.
EP2192197A1 (de) * 2008-11-27 2010-06-02 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Vorhersage der klinischen Reaktion auf die Behandlung mit einem löslichen TNF-Antagonisten oder TNF oder ein TNF-Rezeptoragonist
MX353186B (es) 2009-09-03 2018-01-05 Genentech Inc Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.
CN107496917B (zh) 2010-02-26 2021-06-11 诺沃—诺迪斯克有限公司 包含稳定抗体的组合物
EP3211097A1 (de) * 2010-03-24 2017-08-30 TC LAND Expression Gene und genkombinationen zur vorhersage der frühreaktion oder nichtreaktion von unter einer entzündungskrankheit leidenden patienten auf cytokinabgezielte wirkstoffe (cytd)
WO2011147921A1 (en) 2010-05-28 2011-12-01 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
RU2013140975A (ru) 2011-02-28 2015-04-10 Дженентек, Инк. Биологические маркеры и способы прогнозирования восприимчивости к антагонистам в-клеток
AU2012278802B2 (en) * 2011-07-06 2015-11-26 Société des Produits Nestlé S.A. Assays for detecting neutralizing autoantibodies to biologic therapy with TNF alpha
EP2812445A2 (de) 2012-02-10 2014-12-17 Novo Nordisk A/S Verfahren im zusammenhang mit der behandlung von entzündungserkrankungen und -störungen
HU230680B1 (hu) * 2012-10-19 2017-08-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Diagnosztikai eljárás
US20140255393A1 (en) * 2013-02-28 2014-09-11 Nodality, Inc. Compositions and methods for autoimmune disease
WO2020104705A2 (en) * 2018-11-23 2020-05-28 Katholieke Universiteit Leuven Predicting a treatment response in inflammatory bowel disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US196799A (en) 1877-11-06 Improvement in washing-machines
WO1999023256A1 (en) * 1997-10-30 1999-05-14 Cold Spring Harbor Laboratory Probe arrays and methods of using probe arrays for distinguishing dna

Also Published As

Publication number Publication date
ES2375865T3 (es) 2012-03-07
US20090252740A1 (en) 2009-10-08
CA2652087A1 (en) 2007-11-29
DK2019872T3 (da) 2012-01-16
EP2019872B1 (de) 2011-10-26
WO2007135568A3 (en) 2008-02-28
EP2019872A2 (de) 2009-02-04
US7985549B2 (en) 2011-07-26
WO2007135568A2 (en) 2007-11-29
EP1857559A1 (de) 2007-11-21

Similar Documents

Publication Publication Date Title
ATE530670T1 (de) Verfahren zur vorhersage der ansprechempfindlichkeit auf tnf-blocker
MX2019008675A (es) Variantes de hidroxiesteroide 17-beta deshidrogenasa 13 (hsd17b13) y usos de estas.
DE112008000683A5 (de) Messeinrichtung und Verfahren zur optischen Konzentrationsbestimmung von Blutzucker und/oder Laktat in biologischen Systemen
WO2008115419A3 (en) Gene expression markers for prediction of patient response to chemotherapy
DK2132339T3 (da) Fremgangsmåde til detektering af en analyt i en biologisk matrix
WO2009152928A3 (de) Verfahren zur quantitativen analyse von nukleinsäuren, marker dafür und deren verwendung
ATE546550T1 (de) Verfahren zum nachweis von hpv sowie sonden, primer und kits
EP2570500A3 (de) Genetische Marker für Geisteskrankheiten
BRPI0909611A2 (pt) ''polinucleotídeo isolado, construção de dna recombinante, célula, oleaginosa transgênica, método de aumento do teor total de ácido graxo de oleginosas, método de aumento do teor total de ácido graxo de uma célula de oleaginosa, fragmento de ácido nucleico, fragmento de ácido nucleico isolado e célula fúngica''
EP2372356A4 (de) Sensorchip, biosensorsystem, verfahren zur messung der temperatur biologischer proben, verfahren zur messung der temperatur von blutproben sowie verfahren zur messung der analytkonzentration in blutproben
ATE493517T1 (de) Kontrollgene zur normalisierung von genexpressionsanalysedaten
ATE493512T1 (de) Zusammensetzung zur verstärkung von nukleinsäuren
WO2013056087A3 (en) Compositions and methods for treating and preventing coronary heart disease
DE602004015626D1 (de) Bei brustkrebs
ATE414277T1 (de) Verfahren zur verhinderung der zeitabhängigen rna-expression in biologischen zellen
DE602006015727D1 (de) Verfahren zur messung von plasmaspiegeln von pentraxin ptx3
ATE541056T1 (de) Verwendung von dna-polymerasen wie exoribonukleasen
BRPI0809143B8 (pt) método in vitro para identificar um indivíduo que apresente um risco alterado para desenvolver doença cardíaca coronária (chd) ou aneurisma/dissecção
EA201491821A1 (ru) Модифицированные олигонуклеотиды, включающие тиольные функциональные группы, и их применение для детекции нуклеиновых кислот
MX2010002993A (es) Uso de clec1b para la determinacion de riesgo cardiovascular y trombotico.
WO2011008814A3 (en) Multiplexed measurement of exogenous and endogenous dna
ATE541058T1 (de) Verfahren zum nachweis von wurzelknöllchen- nematoden
Li et al. MiR16 as a microRNA marker applied in species identification
WO2007134718A3 (en) Use of adamts4 gene and protein polymorphisms
ATE475721T1 (de) Verfahren zum nachweis von cytosin-methylierungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2019872

Country of ref document: EP